HMMJ-U:CA:TSX-Global X Marijuana Life Sciences Index ETF (USD)

ETF | Others |

Last Closing

CAD 5.99

Change

-0.09 (-1.48)%

Market Cap

CAD 0.09B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.07 (+0.26%)

CAD 6.19B
XEQT:CA iShares Core Equity Portfolio

+0.15 (+0.42%)

CAD 6.03B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

-0.01 (-0.01%)

CAD 5.57B
PHYS-U:CA Sprott Physical Gold Trust

-0.03 (-0.14%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.12 (+0.31%)

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.18 (+0.39%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

-0.17 (-0.67%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

-0.14 (-1.35%)

CAD 3.29B
ZMMK:CA BMO Money Market Fund ETF Seri..

+0.02 (+0.04%)

CAD 3.24B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.09 (-0.40%)

CAD 2.78B

ETFs Containing HMMJ-U:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.16% 1% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.16% 1% F 7% C-
Trailing 12 Months  
Capital Gain -14.31% 2% F 9% A-
Dividend Return 1.10% 20% F 13% F
Total Return -13.21% 2% F 9% A-
Trailing 5 Years  
Capital Gain -15.04% 9% A- 21% F
Dividend Return 12.29% 49% F 31% F
Total Return -2.75% 9% A- 18% F
Average Annual (5 Year Horizon)  
Capital Gain 23.63% 96% N/A 86% B+
Dividend Return 23.71% 96% N/A 85% B
Total Return 0.08% 16% F 6% D-
Risk Return Profile  
Volatility (Standard Deviation) 59.95% 4% F 15% F
Risk Adjusted Return 39.55% 49% F 52% F
Market Capitalization 0.09B 61% D- 33% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.